WANG Xiaoying,CHEN Liang,LIU Zhanju,et al.Correlation between endoscopic mucosal healing and infliximab trough concentration in patients with Crohn's disease[J].Journal of Tongji University(Medical Science),2022,43(6):793-798. [点击复制]
Correlation between endoscopic mucosal healing and infliximab trough concentration in patients with Crohn's disease
WANG Xiaoying,CHEN Liang,LIU Zhanju,SHI Yanhong
(Department of Gastroenterology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China)
Abstract:
ObjectiveTo analyze the correlation between the trough concentration of infliximab(IFX) and mucosal healing in patients with Crohn's disease(CD). including NRS2002 score, CDAI score, immunosuppressant use, C-reactive protein, serum albumin, hemoglobin, et al. MethodsThe clinical data of 216 patients with CD who received IFX treatment at Shanghai Tenth People's Hospital from July 2017 to September 2020 were retrospectively analyzed. Mucosal healing is defined as CD simplified endoscopy score <3 points. There were 68 patients with mucosal healing and 148 patients with mucosal non-healing, and the trough concentrations of IFX were compared between the two groups. Independent sample t test and chi-square test were used for statistical analysis. ResultsThe median serum IFX trough concentration in the mucosal healing group was significantly higher than that in the mucosal non-healing group(3.4 vs 0.7μg/mL, P<0.001). The optimal trough concentration of IFX for mucosal healing was 2.25μg/mL(AUC 0.75). The multivariate logistic regression analysis showed that IFX trough concentration was significantly correlated with mucosal healing(OR=4.55,95%CI 2.21-8.97). In addition, the anti-infliximab antibody had no correlation with mucosal healing(OR=1.00,P=0.911). ConclusionThe trough concentration of IFX in patients with CD is closely related to endoscopic mucosal healing. The recommended trough concentration of IFX required for mucosal healing is 2.25 μg/mL in this study.